🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Markets Deeper In The Red, Q4 Reports Stay Healthy

Published 01/29/2018, 10:23 PM
Updated 07/09/2023, 06:31 AM
MCD
-
TROW
-
PFE
-
AET
-

Tuesday, January 30, 2018

Stock market futures are down pretty deeply into the red this morning, after an average close on the main indexes of roughly half a percentage point. However, no blame can be placed on Q4 earnings season, which continues to bring about robust results from companies across the spectrum of industries. Asian markets were down slightly overnight, and later this evening we await President Trump’s initial State of the Union address. Later this week, beginning tomorrow, we start to see new data on January jobs numbers.

Keeping with Q4 earnings results, here are 4 leaders in their respective spaces and how well they have performed relative to expectations, particularly the Zacks consensus estimates:

McDonald’s (NYSE:MCD) posted strong quarterly numbers both on top- and bottom-lines ahead of the opening bell today. Earnings of $1.71 per share easily outpaced the $1.59 expected. Revenues reached $5.34 billion in the company’s Q4, ahead of the $5.26 billion in the Zacks consensus.

Beating estimates is nothing new for McDonald’s, whose previous average positive earnings surprise over the past 4 quarters was over 5%. In the quarter just reported, McDonald’s benefited from stronger comps, up 5.5% year over year. For more on MCD’s earnings, click here.

Big Pharma player Pfizer (NYSE:PFE) also beat estimates on both earnings and revenues, with 62 cents per share on $13.70 billion in sales topping the 56 cents and $13.61 billion expected, respectively. Earnings growth year over year was a nice 32%, while revenues were up 1%. Revenue guidance for full-year 2018 remains in range of the current Zacks consensus estimate, whereas earnings guidance of between $2.90-3.00 per share is out ahead of the $2.77 we had earlier expected. For more on PFE’s earnings, click here.

Health insurance major Aetna (NYSE:AET) , on the other hand, posted mixed results for its Q4, with $1.23 per share surpassing the $1.18 we were looking for, but revenues of $14.74 billion lower than the $14.89 billion expected, and down further from the $15.72 billion a year ago. Enrollment is down as Congress continues to chip away at the Affordable Care Act, which was good for Aetna: the previous 4 quarters generated an average 23% positive earnings surprise. For more on AET’s earnings, click here.

Global asset management firm T. Rowe Price (NASDAQ:TROW) , a Zacks Rank #2 (Buy) stock, also posted earnings and revenue beats for its Q4 report: $1.52 per share outperformed the Zacks consensus by 7 cents, while the $1.29 billion in revenues did better than the $1.27 billion estimated and the $1.09 billion in the year-ago quarter. Bottom-line earnings provided a bigger surprise than the previous 4 quarters’ +1.53% average. For more on TROW’s earnings, click here.

Mark Vickery
Senior Editor

Questions or comments about this article and/or its author? Click here>>

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.

Click here for Zacks' private trades >>



Pfizer, Inc. (PFE): Free Stock Analysis Report

T. Rowe Price Group, Inc. (TROW): Free Stock Analysis Report

Aetna Inc. (AET): Free Stock Analysis Report

McDonald's Corporation (MCD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.